On April 27, 2026, XOMA Royalty Corp announced a merger agreement with Ligand Pharmaceuticals, where shareholders will receive $39.00 per share in cash and contingent value rights. This merger will lead to a holding company reorganization and includes significant stipulations on shareholder approval and future obligations.